TLDR:
Key Points:
- Adaptilens, a pre-clinical biotech company based in Boston, raised $17.5M in Series A funding.
- The funding round was led by Perceptive Xontogeny Venture Funds (PXV Funds), with additional investments from Pillar VC, 380 Cap, and Accanto Partners.
Adaptilens, led by Founder and CEO Liane Clamen, focuses on advancing the standard of care for cataract surgery with its accommodating intraocular lens (A-IOL). The A-IOL responds to the eye’s natural signal to focus, eliminating the need for eyeglasses or contact lenses. The funding will be used to drive the development of the A-IOL through first-in-human trials.
Liane Clamen expressed excitement about the funding, highlighting the company’s goal to provide a biomimetic option for cataract surgery that restores youthful vision. With a focus on leveraging the eye’s natural design, Adaptilens aims to offer a best-in-class A-IOL solution for individuals in need of cataract surgery.
